Showing 15 posts of 97 posts found.


Breakthrough eczema drug given FDA approval

March 29, 2017
Research and Development, Sales and Marketing Dupixent, Regeneron, Sanofi

Regeneron and Sanofi have received approval for its eczema treatment, Dupixent, by the FDA. The treatment will be the first …


GSK and Regeneron partner with Biobank to analyse 500,000 genetic profiles

March 23, 2017
Research and Development Biobank, GSK, Regeneron

GlaxoSmithKline and Regeneron Pharmaceuticals are to band together in a joint effort with UK Biobank – “the world’s most detailed …

Sanofi & Regeneron deflect Amgen’s legal marketing block on Praluent

February 9, 2017
Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, praluent

Sanofi and Regeneron have successfully won in a US Court ruling calling for the suspension of the permanent injunction of …

Sanofi & Regeneron’s arthritis drug scores first approval following FDA rejection

February 1, 2017
Research and Development, Sales and Marketing Actemra, Humira, Kevzara, Regeneron, Roche, Sanofi, sarilumab

Kevzara (sarilumab), a interleukin-6 (IL06) receptor antibody developed by Sanofi and Regeneron and the first real competitor to Roche’s Actemra …


Regeneron agrees ownership of HQ for $720m after 25 years

January 25, 2017
Manufacturing and Production, Medical Communications Regeneron

After leasing the property for 25 years, Regeneron has agreed to take ownership of its headquarters and buy the Landmark …


Amgen’s patent win upheld against Sanofi-Regeneron

January 4, 2017
Medical Communications, Research and Development Amgen, Regeneron, Sanofi, patent

In March 2016, Amgen won two major patent cases against Sanofi and Regeneron over their drug, Praleunt, after it was …

FDA rejects Sarilumab due to production facility issues

October 31, 2016
Manufacturing and Production, Sales and Marketing FDA, Regeneron, Sanofi, sarilumab

The US Food and Drugs administration has decided to reject the application for Sarilumab, Regeneron and Sanofi’s rheumatoid arthritis treatment, …


Regeneron and Teva’s experimental drug halted by FDA clinical hold

October 17, 2016
Manufacturing and Production Regeneron, Teva, back pain, osteoarthritis

Regeneron Pharmaceuticals and Teva Pharmaceuticals had only just agreed a deal worth a potential $2.6 billion to co-develop Regeneron’s fasinumab …


Regeneron’s Eylea fails combination study endpoint

October 3, 2016
Research and Development, Sales and Marketing Eylea, Regeneron

Regeneron has announced that its eye drug Eylea (aflibercept) failed its primary endpoint in a mid-stage trial investigating its effectiveness …


Teva and Regeneron team up for $2.6 billion pain treatment development

September 21, 2016
Research and Development, Sales and Marketing Regeneron, Teva, fasinumab, osteoarthritis

Teva and Regeneron have entered an agreement worth up to $2.6 billion to develop and market the latter’s experimental nerve …


Sanofi & Regeneron’s Praluent cholesterol treatment smashes Phase III target

August 30, 2016
Manufacturing and Production, Research and Development Regeneron, Sanofi, apheresis, cholesterol, phase III

Sanofi and Regeneron have announced that their Praluent injection generated positive Phase III results investigating patients with an inherited form …


Amgen, Sanofi cholesterol medicines “not cost-effective”, need to drop price by two-thirds

August 17, 2016
Research and Development, Sales and Marketing Amgen, QALY, Regeneron, Repatha, Sanofi, cost effective, cost-effective, praluent

A new study published in JAMA has suggested that Amgen, Sanofi and Regeneron would have to reduce their prices for …


Eylea sales jump helps boost Regeneron in Q2 results

August 5, 2016
Medical Communications, Research and Development 2016, Eylea, Q2, Regeneron, results

Regeneron Pharmaceuticals has published positive Q2 results with a 27% rise in Eylea (aflibercept) sales in the US helping to …


EMA accepts MMA for rheumatoid arthritis treatment Sarilumab

August 1, 2016
Research and Development, Sales and Marketing EMA, MAA, Regeneron, Sanofi, sarilumab

Sanofi and Regeneron Pharmaceuticals have announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for …

Sanofi, Regeneron say cholesterol drug Praluent approved in Japan

July 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Japan, Regeneron, Sanofi, cardiovascular, cholestrol, praleunt

Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) said the lawmakers in Japan have granted marketing and manufacturing authorization for …

Latest content